Biotech sponsors evaluating a clinical trial partner for biotech programs face a crowded market. The right partner can mean the difference between hitting enrollment targets on schedule and watching timelines slip. This guide breaks down what to look for when selecting a full-service clinical trial partner for Phase I through Phase III programs — and the questions every biotech sponsor should ask before signing.
Why clinical trial partner selection matters more for biotech than for large pharma
Large pharmaceutical companies have internal clinical operations teams, established site relationships, and the budget to absorb delays. Biotech sponsors typically do not. A failed enrollment cycle or a quality issue that triggers a site audit can derail a program entirely — and in a biotech, that can mean the difference between reaching the next funding milestone and running out of runway.
The clinical trial services market includes dozens of site networks, CROs, and hybrid organizations that claim to offer full-service support. Understanding what actually separates a high-performing partner from an average one requires looking beyond capabilities claims and asking for evidence.
The 5 things that define a strong clinical trial partner for biotech
1. A model built for community access, not just research centers
Traditional standalone research sites — facilities that operate separately from a patient’s regular healthcare — are increasingly showing their limitations. Patients have to travel to unfamiliar locations, their regular physicians are not involved, and dropout rates are higher because participation feels disconnected from care.
The most effective clinical trial partners have moved toward models that integrate research into existing healthcare settings. When research staff are embedded inside medical practices where patients are already being treated, several things happen: patients hear about studies from physicians they already trust, enrollment barriers drop, and retention improves because participation fits naturally into the patient’s existing care routine.
What to ask: What percentage of your enrollment comes from internal sources — physician referrals and EMR outreach — versus paid external advertising? A network that relies heavily on paid advertising is more expensive to operate and produces less engaged participants.
FOMAT’s embedded model is built around this principle. Research staff operate inside partner medical practices, and the majority of participants enroll through physician referrals and community outreach — not paid campaigns.
2. Demonstrated diversity enrollment
The FDA’s guidance on diversity in clinical trials and subsequent legislation have made diverse enrollment a measurable deliverable — not an aspiration. Sponsors who cannot demonstrate diverse participant populations face increasing scrutiny from regulators and a growing gap between their trial data and the real-world populations who will use the drug.
Genuine diversity in enrollment does not come from demographic checkboxes. It comes from authentic relationships with underserved communities, bilingual staff, and a presence in geographic areas where those communities live and receive care.
What to ask: What is your diversity enrollment rate across all studies in the past 24 months? Can you show us enrollment demographics broken down by therapeutic area?
FOMAT has built its network around communities that are historically underrepresented in clinical research — including large Hispanic populations in California’s Central Coast and Central Valley — with bilingual teams and community partner networks that drive authentic participation.
3. Phase I to Phase III continuity
Switching clinical trial partners between phases creates friction — new contracts, new site qualification processes, new relationships, and a loss of institutional knowledge about the patient population and the protocol. For a biotech managing a program from first-in-human to pivotal Phase III, having a single partner capable of supporting the full arc of development is a significant operational advantage.
Not all site networks can credibly support both early-phase and late-phase work. Phase I requires a dedicated unit with intensive safety monitoring, pharmacokinetics capabilities, and the ability to handle first-in-human studies under tight regulatory oversight. Phase II and III require scale, community access, and enrollment infrastructure.
What to ask: Do you operate a dedicated Phase I unit, or do you handle early-phase studies at general outpatient sites? What is your first-in-human experience?
FOMAT operates a dedicated early-phase unit for Phase I studies alongside its outpatient Phase II–III network, giving sponsors a single partner for the full development continuum.
4. Quality systems that protect data integrity from day one
Quality in clinical trials is not something that can be audited in at the end of a study. By the time a quality issue surfaces at closeout, the damage to the dataset may already be irreversible. Strong clinical trial partners build quality oversight into every stage of execution — from site activation through the last patient visit.
eSource, eConsent, and eRegulatory readiness are no longer optional. Remote monitoring is now standard expectation from most sponsors and CROs. Partners who are still operating on paper-based systems or whose sites are not ready for remote monitoring represent an operational risk that biotech sponsors cannot afford.
What to ask: Are all your sites eSource, eConsent, and eRegulatory ready? How do you conduct quality oversight during a study — continuously or only at closeout? What is your participant retention rate across all studies?
5. Site activation speed backed by data
Every site network claims fast activation. Very few can back that claim with data. For biotech sponsors, time from award to first patient enrolled is directly tied to cash burn and program timelines. A partner that takes six months to activate sites is not a partner — it is a liability.
Fast activation requires pre-qualified investigators, standardized start-up playbooks, regulatory and contract templates that are already in place, and research infrastructure that does not need to be built from scratch for every study.
What to ask: What is your average time from award to site activation? What is your record? Can you show us data from studies in our therapeutic area?
Because FOMAT’s research staff are already operating inside partner practices before a study begins, site activation follows a structured playbook rather than starting from zero — enabling some of the fastest activation timelines in the industry.
Red flags to watch for when evaluating clinical trial services
- No data to back claims. Any partner that cannot provide enrollment rates, diversity statistics, activation timelines, or retention data by therapeutic area should be treated with caution.
- Heavy reliance on paid advertising for recruitment. It is expensive, produces lower-quality leads, and is a sign the network does not have authentic community relationships.
- Sites that are not technology-ready. Paper-based processes, no eSource capability, and no remote monitoring readiness are operational risks in 2026.
- No Phase I capability. If your program may include early-phase work, a partner without a dedicated Phase I unit will require you to split your program across two organizations.
- Geographic concentration in urban research hubs only. Networks that operate only in major metropolitan areas will struggle to deliver the diverse, community-based enrollment that regulators and science increasingly require.
What full-service clinical trial services should include
A genuinely full-service clinical trial partner should be able to support a biotech sponsor across the following areas without requiring multiple vendors:
- Phase I early-phase unit with first-in-human and PK/PD capabilities
- Phase II–III multi-site execution with centralized quality oversight
- EMR-based patient prescreening and identification
- Multilingual community outreach and bilingual study staff
- eSource, eConsent, eRegulatory, and remote monitoring readiness
- Diversity enrollment with documented demographic data
- Centralized contracts, budgets, regulatory, and start-up support
FOMAT offers this full range of services through its embedded research model, with 40+ active sites across the United States. To discuss your program’s needs, contact the business development team at [email protected] or call (805) 483-1185.
Frequently asked questions
What is a full-service clinical trial partner?
A full-service clinical trial partner provides end-to-end support for clinical study execution — from site selection and activation through enrollment, data collection, quality oversight, and closeout. Full-service partners handle regulatory coordination, patient recruitment, and quality monitoring, allowing biotech sponsors to focus on their drug development program rather than trial operations.
What is the difference between a site network and a CRO?
A site network owns or manages clinical research sites where studies are physically conducted. A CRO (Contract Research Organization) typically manages the operational and regulatory aspects of a trial on behalf of a sponsor but does not own sites. Many biotech sponsors work with both — a CRO for trial management and a site network for execution. Site networks like FOMAT can work alongside CROs or directly with sponsors.
How do biotech companies find and select clinical trial sites?
Biotech sponsors typically identify sites through feasibility questionnaires, CRO recommendations, industry databases, and direct outreach to site networks. Working with an established network significantly reduces the time and complexity of site selection compared to engaging individual sites one at a time. For sponsors with diversity enrollment requirements, partnering with a network that has established community relationships is essential.
What therapeutic areas does FOMAT support for biotech clinical trials?
FOMAT has active experience across cardiovascular and circulatory diseases, digestive diseases and gastroenterology, endocrinology and metabolic disorders, infectious diseases and vaccines, nephrology, neurology, oncology, ophthalmology and retina, pediatrics and adolescents, rheumatology, and urology. Contact the business development team at [email protected] to discuss feasibility for your specific indication.
How can a biotech sponsor partner with FOMAT?
Biotech sponsors and CROs can contact FOMAT’s business development team at [email protected] or (805) 483-1185. FOMAT provides feasibility assessments and site-specific metrics for any therapeutic area. Learn more at fomatmedical.com/phase-ii-iii-capabilities.